



## Review article

## Impact of aging immune system on neurodegeneration and potential immunotherapies

Zhanfeng Liang<sup>a,1</sup>, Yang Zhao<sup>a,1</sup>, Linhui Ruan<sup>b,1</sup>, Linnan Zhu<sup>a,1</sup>, Kunlin Jin<sup>b,c</sup>, Qichuan Zhuge<sup>b</sup>, Dong-Ming Su<sup>c,\*</sup>, Yong Zhao<sup>a,\*\*</sup><sup>a</sup> State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, PR China<sup>b</sup> First Affiliated Hospital, Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, PR China<sup>c</sup> Department of Cell Biology & Immunology, and Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA

## ARTICLE INFO

## Article history:

Received 23 July 2015

Received in revised form 25 July 2017

Accepted 28 July 2017

Available online 4 August 2017

## Keywords:

Immune system

Aging

Inflammation

Neurodegeneration

Immunotherapy

## ABSTRACT

The interaction between the nervous and immune systems during aging is an area of avid interest, but many aspects remain unclear. This is due, not only to the complexity of the aging process, but also to a mutual dependency and reciprocal causation of alterations and diseases between both the nervous and immune systems. Aging of the brain drives whole body systemic aging, including aging-related changes of the immune system. In turn, the immune system aging, particularly immunosenescence and T cell aging initiated by thymic involution that are sources of chronic inflammation in the elderly (termed inflammaging), potentially induces brain aging and memory loss in a reciprocal manner. Therefore, immunotherapeutics including modulation of inflammation, vaccination, cellular immune therapies and “protective autoimmunity” provide promising approaches to rejuvenate neuroinflammatory disorders and repair brain injury. In this review, we summarize recent discoveries linking the aging immune system with the development of neurodegeneration. Additionally, we discuss potential rejuvenation strategies, focusing aimed at targeting the aging immune system in an effort to prevent acute brain injury and chronic neurodegeneration during aging.

© 2017 Elsevier Ltd. All rights reserved.

## Contents

1. Introduction	3
2. Immune characteristics of acute brain injury and age-related chronic neurodegeneration	4

**Abbreviations:** A $\beta$ , amyloid-beta; AD, Alzheimer's disease; ADCC, antibody dependent cell-mediated cytotoxicity; ALS, amyotrophic lateral sclerosis; APCs, antigen presenting cells; APOE, apolipoprotein E; APP, amyloid precursor protein; APP/PS1, amyloid precursor protein and presenilin;  $\alpha$ -Syn,  $\alpha$ -synuclein protein; BBB, blood-brain barrier; BDNF, brain-derived neurotrophic factor; C/EBP, CCAAT/enhancer binding protein; CMV, cytomegalovirus; CNS, central nervous system; COX, cyclooxygenase CP choroid plexus; CRP, C-reactive protein; CSEF, circulating systemic environmental factor; CSF, cerebrospinal fluid; CTFs, C-terminal fragments; CTL, Cytotoxic T Lymphocytes; EAE, experimental autoimmune encephalomyelitis; GM-CSF, granulocyte-macrophage colony-stimulating factor; GCs, glucocorticoids; GnRH, gonadotropin-releasing hormone; GR, glucocorticoid receptor; HIV, human immunodeficiency virus; IFN, interferon; IL- $\beta$ , interleukin- $\beta$ ; i.p., intraperitoneal; i.v., intravenous; LPS, lipopolysaccharides; LTP, long-term potentiation; M $\phi$ , macrophage; MBL, mannan-binding lectin; MBP, myelin basic protein; MCAO, middle cerebral artery occlusion; MHC, major histocompatibility complex; miR, microRNAs; MOG, myelin oligodendrocyte glycoprotein; MS, Multiple sclerosis; mTOR, mechanistic target of rapamycin; NF- $\kappa$ B, nuclear factor kappa-light-chain-enhancer of activated B cells; NFT, neurofibrillary tangles; NLRP3, nod-like receptor protein 3; NOS2, nitric oxide synthase; NSAIDs, non-steroidal anti-inflammatory drugs; NSCs, neuron stem cells; NT-3, neurotrophin-3; PD, Parkinson's disease; POCD, postoperative cognitive dysfunction; ROS, reactive oxygen species; RRMS, relapse-remission multiple sclerosis; SA- $\beta$ Gal, senescence-associated beta-galactosidase; SASP, senescence-associated secretory phenotype; TCR, T cell receptor; TCv, T-cell vaccine; TGF- $\beta$ , transforming growth factor-beta; Th1/2/17, T helper cell 1/2/17; TNF- $\alpha$ , tumor necrosis factor-alpha; Treg, regulatory T cell; TREM2, triggering receptor expressed on myeloid cells 2; WT, wild-type.

\* Corresponding author at: Department of Cell Biology and Immunology, University of North Texas Health Center at Fort Worth, 3500 Camp Bowie Blvd Fort Worth, TX, 76107, USA.

\*\* Corresponding author at: Transplantation Biology Research Division, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beichen West Road 1-5, Chaoyang District, Beijing, 100101, China.

E-mail addresses: [dongming.su@unthsc.edu](mailto:dongming.su@unthsc.edu) (D.-M. Su), [zhaoy@ioz.ac.cn](mailto:zhaoy@ioz.ac.cn) (Y. Zhao).

<sup>1</sup> These authors contributed equally to this work.

2.1.	Neuroinflammation and degeneration	4
2.2.	Immunopathological alterations in age-related neurodegenerative diseases	4
2.2.1.	Acute brain injury: ischemic stroke and brain trauma	4
2.2.2.	Typical autoimmune neurodegenerative disorder: MS	5
2.2.3.	Aging-associated neurodegenerative diseases: AD and PD	5
2.2.4.	Neuroinflammation in the aging-related cognitive decline	6
2.2.5.	Genetic factors and environmental factors on the pathogenesis of age-related neurodegenerative diseases	6
3.	Role of inflammation in neurodegenerative diseases	7
3.1.	Pro-inflammatory factor production by SASP in age-related neurodegeneration	7
3.2.	Inflammasomes in age-related neurodegeneration	8
3.3.	Exosome in age-related neurodegeneration	8
3.4.	Inflamaging	9
4.	Role of complement system in neurodegenerative diseases	9
4.1.	Role of complement system on ischemic stroke	10
4.2.	Role of complement system on AD and PD	10
5.	Role of T cells in neural de/re-generation during aging	11
5.1.	T cells developed in the aged thymus	11
5.2.	Role of T cell subsets in age-related neurodegenerative diseases	12
5.2.1.	Th1 cells	12
5.2.2.	Th17 cells	13
5.2.3.	CD8 <sup>+</sup> CTLs	13
5.2.4.	$\gamma\delta$ T cells	13
5.3.	Potential beneficial roles of T cells in age-related neurodegeneration	14
5.3.1.	Tregs	14
5.3.2.	Th2 cells	14
5.3.3.	Brain antigen-specific CD4 <sup>+</sup> T cells are required for maintenance of brain plasticity	15
6.	Neuro-endocrine networks control immune system	15
6.1.	Glucocorticoids serve as a double-edged sword in neuroinflammation	15
6.2.	Evidence of direct neuronal regulation of immune cells and the immune response	16
7.	Immunological therapeutic strategies for age-related neurodegeneration	16
7.1.	Innate immunity-based immunotherapies for the alleviation of neuroinflammation	17
7.2.	Improvement of cellular microenvironment-based therapy	18
7.2.1.	Balancing the aged CNS inflammatory process	18
7.2.2.	Tregs as therapeutics for CNS inflammation	18
7.3.	Soluble factor: young serum-derived CSEF improves the aged stem cell environment, and potentially improves the cellular immune system environment	18
7.4.	Vaccination therapy	19
7.4.1.	Vaccination in autoimmune neurodegeneration	19
7.4.2.	Therapeutic vaccination in AD and PD	19
8.	Conclusions	20
	Acknowledgements	20
	References	20

## 1. Introduction

The mutual interactions and dependency of nervous and immune systems have been recognized for long and recently cause more and more attentions (McAllister and van de Water, 2009; Trakhtenberg and Goldberg, 2011). This is simply because the nervous and immune systems interact and crosstalk each other over many physiological processes, like development, homeostasis, pathogenesis, and aging. The immune system has both detrimental and beneficial effects on the nervous system. The autoimmune demyelinating disease multiple sclerosis (MS) is a typical example of an abnormal immunity-induced pathological damage in nervous system (Naegele and Martin, 2014). The central nervous system (CNS) in turn induces immunological changes via the neuro-endocrine network (Procaccini et al., 2014; Rosas-Ballina and Tracey, 2009; Tanriverdi et al., 2003). Stroke-induced global immunosuppressant effect is a well-known example (Meisel and Meisel, 2011). However, the beneficial effects of the immune system on the nervous system have only recently and gradually been recognized (Schwartz et al., 2013). For example, the immune cells and inflammation have been demonstrated to be required for brain healing (Raposo et al., 2014; Ziv et al., 2006a). Even autoimmunity can play both detrimental and beneficial effects to the CNS. While autoimmunity induced neuroinflammation and

neurodegeneration (Bhat and Steinman, 2009), brain antigen-induced “autoimmunity” (so-called “protective autoimmunity”) may be involved in the maintenance of CNS functional integrity (Moalem et al., 1999).

The interaction and mutual dependency between the nervous and immune systems lead to reciprocal affects on both systems during aging process. It is a question that which system goes first during neurodegeneration. As we know, cellular immune system aging, particularly of the T cell system resulting from age-related thymic involution which typically starts as early as in adolescence (Gui et al., 2012), takes place far before brain aging. Therefore, the significant age-related alterations of the immune system should causally influence nervous system homeostasis and regeneration. It is recognized that natural aging bring about immune activation and cell infiltration into the brain (Lucin and Wyss-Coray, 2009), which is probably due to aging-induced inflammatory conditions. This aging-relevant condition possibly promoted by pro-inflammatory cytokines produced by glial cells and senescent cells in other tissues would significantly increase the permeabilization of the blood-brain barrier (BBB), and recruit more immune cells to the CNS (Deverman and Patterson, 2009). Immunosenescence is believed to be directly associated with brain aging and memory loss (Di Benedetto et al., 2017; Ron-Harel and Schwartz, 2009). On the other hand, age-related neurodegeneration and the subsequent

Download English Version:

<https://daneshyari.com/en/article/5739063>

Download Persian Version:

<https://daneshyari.com/article/5739063>

[Daneshyari.com](https://daneshyari.com)